[Extensive trial of a monoclonal immunoenzyme test system for the detection of HBsAg in donors and patients].
The enzyme immunoassay system for hepatitis B diagnosis developed on the basis of monoclonal antibodies to hepatitis B virus surface antigen (HBsAg), EIAmca, was demonstrated to detect twice as many antigen-containing donor sera than DHA test, and 9-10 times more than CIEP. By means of EIAmca, HBsAg could be detected in a larger number of patients' sera and in higher dilutions of the sera. This attests to a higher sensitivity of the developed EIAmca system as compared with diagnostic systems of CIEP, DHA test and EIApca.